On Wednesday, the UK medicines regulator the National Institute of Health and Care Excellence (“NICE”) approved the use of the weight loss drug Mounjaro on the NHS.
It’s not clear that this drug is safe in the long term so why would NICE approve it to be provided for free to potentially millions of people?
It is claimed Mounjaro, the brand name of tirzepatide, is more effective than semaglutide, known as Ozempic and Wegovy.
Writing for the Daily Mail, Dr. Renée Hoenderkamp expressed concerns that not only will the availability of the drugs at taxpayers’ expense undermine the idea that people should take responsibility for their own lifestyle choices, but it will add to the strain on the already overstretched NHS Budget.
The principle – that the NHS will bankroll irresponsible behaviour and thereby encourage it – is a troubling one, she said.
Mounjaro which costs £122 per month will initially be offered to 222,000 people, a fraction of the 3.4 million in Britain who are classified as obese. “Once the Mounjaro jab is prescribed it will be difficult, if not impossible, for the NHS to keep a lid on the numbers,” Dr. Hoenderkamp said.
If the injections were given to 3.4 million people, that would equate to nearly £415 million per month.
Additionally, she said, “it is not clear that the drug is safe in the long term and its manufacturer has yet to share full details of the research it has funded so far. Side-effects may take years, even decades to emerge, which means that this step amounts to an expensive leap into the unknown.”
So why are the NHS embarking on this madness?
Sharing her article on Twitter Dr. Hoendekamp said, “Jabs for obesity will bankrupt the NHS and bring unknown and known side effects. BUT will make big pharma wealthier than they ever imagined from one patient group!”
Her accusation is not without substance. The day before she had tweeted: “Eli Lilly (maker of the obesity Jab) has donated £279 million to a Government collaboration and what do they want in return … their jab into the NHS” and included a hyperlink to the UK government press release below.
On 14 October, the UK government announced a memorandum of understanding with Lilly. Under the agreement, the pharmaceutical giant will launch the first ‘Lilly Gateway Labs’ innovation accelerator in Europe. “This facility will support early-stage life sciences businesses to develop transformative medicines by providing lab space, mentorship and potential financial backing to rocket future growth in the sector,” the press release said. It continued:
Obesity is the second biggest preventable cause of cancer and a major contributor to ill health that prevents people from participating fully in work. This collaboration will bring together treatments and technologies developed by the life sciences sector and the health system seeking to demonstrate improved long-term health outcomes for those living with obesity.
The collaboration with Lilly aims to set the stage for government to work with industry to trial innovative approaches to treating obesity as part of a rounded package of care.
Driving economic growth to improve the lives of hardworking British people is this government’s number one mission. The life sciences sector – which drove £800 million in foreign direct investment into the UK in 2023 – sits at the heart of these plans.
Landmark collaboration with largest pharmaceutical company, UK Government, 14 October 2024
Unsurprisingly, corporate media is being used to campaign for and market Mounjaro. Pushing for more people to be offered Lilly’s weight loss injections, paid for by the NHS, The Times wrote:
NICE, the health watchdog, has ruled that 3.4 million adults are eligible for Mounjaro, the most effective so far in a revolutionary new class of anti-obesity injections. But a lack of NHS capacity means only 220,000 of these patients, fewer than one in ten, will be given the drug over the next three years, after spending years on waiting lists.
Most obese people will instead be directed to the NHS app offering weight-loss tips. NICE said they would “have to wait” for drugs in an effort to “protect other vital NHS services.” Delays in giving the jabs threaten to undermine a promise by Sir Keir Starmer to bring down waiting lists while a rise in obesity-related diseases piles pressure on the health service.
Millions of obese people will be denied weight-loss jabs on the NHS, The Times, 5 December 2024
We have attached The Times article below so you can read for yourself how hard The Times is campaigning for more people to be given these injections.
Dr. Hoendenkamp responded to The Times article. “Open your eyes … these people do not care about your health, just the money,” she said and quoted The Times as saying, “Eli Lilly, the firm that manufactures Mounjaro, urged the health service to ‘ramp up’ its introduction of weight-loss drugs.”
“This is the company who has just managed to get NICE to approve their obesity jab for the NHS …. Give a bit of money to the government, get a licence to print money …,” she added.
Source: https://expose-news.com/2024/12/07/big-pharma-collborates-with-uk-government/
Bitchute: https://www.bitchut,e.com/channel/YBM3rvf5ydDM/
Telegram: https://t.me/Hopegirl587
EMF Protection Products: www.ftwproject.com
QEG Clean Energy Academy: www.cleanenergyacademy.com
Forbidden Tech Book: www.forbiddentech.website
